Search
Search filters
Type
Audience
Category
Issue
Last updated
- 20231 results available
- 20222 results available
- 20216 results available
- 20181 results available
- 20162 results available
- 20151 results available
- 20131 results available
- 20122 results available
- 20091 results available
- 20072 results available
- 20063 results available
- 20053 results available
- 20042 results available
- 20031 results available
- 20023 results available
- 20011 results available
Recall class
Displaying 1 - 15 of 32 items.
AstraZeneca COVID-19 Vaccine and COVISHIELD: Risk of Capillary Leak Syndrome
AlertHealth professional risk communication | 2021-06-29
AstraZeneca COVID-19 Vaccine and COVISHIELD: Risk of Thrombosis with Thrombocytopenia
AlertHealth professional risk communication | 2021-03-24
Authorization of AstraZeneca COVID-19 Vaccine with English-only Vial and Carton Labels
AlertHealth professional risk communication | 2021-03-01
Importation of AstraZeneca COVID-19 Vaccine with English-only Vial and Carton Labels (US-Labelled Supply)
AlertHealth professional risk communication | 2021-03-31
Authorization of COVISHIELD with English-only Vial and Carton Labels
AlertHealth professional risk communication | 2021-03-01
Health Canada issues label change on the AstraZeneca and COVISHIELD COVID-19 vaccines
AlertPublic advisory | 2021-06-29
Archived – Important Safety Information Regarding Accolate® (Zafirlukast) and Hepatic Effects – AstraZeneca
AlertHealth professional risk communication | 2002-12-18
Important Safety Information on Oxeze (formoterol fumarate dihydrate) Turbuhaler – AstraZeneca Canada Inc. – For Health Professionals
AlertHealth professional risk communication | 2005-09-09
Association of CRESTOR® (rosuvastatin) with Muscle -Related Adverse Events – AstraZeneca Canada Inc. – For Health Professionals
AlertHealth professional risk communication | 2005-03-11
Archived – Important Safety Information Regarding Medication Errors Resulting from Confusion Between Seroquel® and Serzone-5HT2® – AstraZeneca and Bristol-Myers Squibb
AlertHealth professional risk communication | 2002-10-31
Pulmicort Turbuhaler (budesonide) powder for oral inhalation - Potential device failure - For Health Professionals
AlertHealth professional risk communication | 2012-07-26
Pulmicort Nebuamp - (0.125 mg/mL, 0.25 mg/mL, 0.5 mg/mL)
RecallHealth product recall | 2013-02-18
Archived - Iressa (gefitinib) 250 mg Tablets - Advisories, Warnings, and Recalls for Health Professionals
AlertHealth professional risk communication | 2006-06-05
Important Safety Information on IRESSA (gefitinib) - For Health Professionals
AlertHealth professional risk communication | 2007-10-11
Iressa (gefitinib) 250 mg Tablets - Advisories, Warnings and Recalls for Health Professionals
AlertHealth professional risk communication | 2005-08-26